Biologics patent expiry to positively impact US pharma, says report
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
List view / Grid view
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
15 June 2016 | By Victoria White, Digital Content Producer
The proceeds will fund Phase II development of AAI202 - a novel antibiotic combination designed to treat drug-resistant Gram-negative bacterial infections...